Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 3Seizures 3Sturge-Weber Syndrome 2Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Lennox Gastaut Syndrome 1Glioblastoma 1Epilepsy 1Epilepsies, Myoclonic 1Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Breast Neoplasms 1Arthralgia 1Anxiety Disorders 1

Interventions

perampanel 1Immunoglobulins, Intravenous 1Cannabidiol 1Anticonvulsants 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Drug Resistant Epilepsy × Cannabidiol × Clear all
NCT02332655 2022-03-02

Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 1/2 Completed
5 enrolled 8 charts

Drug Resistant Epilepsy, Sturge-Weber Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡